Clinical trials: Sporadic Inclusion Body Myositis
Sporadic Inclusion Body Myositis
Blood-flow Restricted Exercise in Inclusion Body Myositis
This study evaluates the effects of a low-intensity blood-flow restricted exerciser protocol on patient reported physical function, in patients with sporadic inclusion body myositis.
- Trial name
- NCT02317094
- Testing
- Blood-flow restricted training, Care as usual
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- University of Southern Denmark
Polymyositis, Dermatomyositis
Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive to traditional immunosuppressive and/or…
- Trial name
- NCT01148810
- Testing
- BAF312
- Where
- 6 sites in United States, Czechia and 3 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Inclusion Body Myositis (IBM), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
The Aim of the Study is to Characterize Patients Exhibiting Muscular Atrophy and Weakness Who Require a Muscle Biopsy for Diagnosis (IBM vs Atypical MND), Through an Innovative Technique Which Enables the Evaluation of the Neuromuscular Junction Involvement in Each Condition
The aim of the study is to characterize 30 patients exhibiting muscular atrophy and weakness who require a muscle biopsy for diagnosis (suspected inclusion body myopathy vs atypical motor neuron disease), through an innovative…
- Trial name
- TDP-signatures (NCT07796776)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Polymyositis, Dermatomyositis
Anakinra in Myositis
To investigate the effect of the interleukin-1 (IL-1) blocking agent, anakinra, in patients with treatment-resistant inflammatory myopathies.
- Conditions
- Polymyositis, Dermatomyositis, Inclusion Body Myositis
- Trial name
- NCT01165008
- Testing
- Anakinra
- Where
- Sweden
- Sponsor
- Karolinska Institutet
Inclusion Body Myositis
Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis
Comparison of a group of 20 IBM patients with 20 controls matched on age, gender and weight.
- Trial name
- IBMan (NCT00898989)
- Where
- France
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Institut de Myologie, France
IBM, Inclusion Body Myositis
Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis
This study will evaluate whether neuromuscular ultrasound and MRI can be used as imaging markers of bulbar involvement and swallowing dysfunction in individuals with inclusion body myositis (IBM).
- Conditions
- IBM, Inclusion Body Myositis, Myopathy, Myositis
- Trial name
- NCT07823101
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Inclusion Body Myositis
Study of Arimoclomol in Inclusion Body Myositis (IBM)
Funding Source - FDA Office of Orphan Products Development (OOPD). The purpose of this study is to evaluate the safety and efficacy of the study drug, arimoclomol in IBM patients.
- Trial name
- NCT02753530
- Testing
- Arimoclomol
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 152 people
- Sponsor
- ZevraDenmark
Pompe Disease (Late-onset), Inclusion Body Myositis
Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
The primary aim of this nationwide, explorative, cross-sectional study in Germany is to characterize the prevalence, severity and quality of musculoskeletal pain in adult patients with late-onset Pompe disease (LOPD).
- Conditions
- Pompe Disease (Late-onset), Inclusion Body Myositis, Spinal Muscular Atrophy Type 3, FSHD
- Trial name
- NCT05272969
- Testing
- Beck depression inventory fast screen (Questionnaire), Brief Pain Inventory (BPI) (Questionnaire), German Pain Inventory (Questionnaire)
- Where
- Germany
- Volunteers
- 95 people
- Sponsor
- LMU Klinikum
Inclusion Body Myositis
Cell Therapy for IBM by Muscle Injection of ADSVF
Inclusion Body Myositis is a slowly but disabling myopathy, the most frequent in patients over 50 years old. No treatments (in particular immunosuppressive) are known to be efficient.
- Trial name
- ADSVF-in-IBM (NCT05032131)
- Testing
- ADSVF
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Becker Muscular Dystrophy, Sporadic Inclusion Body Myositis
Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis
The investigators are performing a gene therapy clinical trial in Becker muscular dystrophy (BMD) and sporadic inclusion body myositis (sIBM) patients.
- Trial name
- NCT01519349
- Testing
- rAAV1.CMV.huFollistatin344
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Nationwide Children's Hospital
Inclusion Body Myositis (IBM)
Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis
ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study…
- Trial name
- NCT06450886
- Testing
- Ulviprubart (ABC008)
- Where
- 21 sites in United States, Australia
- Volunteers
- 270 people
- Sponsor
- Abcuro, Inc.
Sporadic Inclusion Body Myositis
An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
This extension study will provide data to further evaluate the efficacy, safety, and tolerability of three doses of BYM338 and to assess the long-term effects of BYM338 in patients with sporadic inclusion body myositis.
- Trial name
- NCT02573467
- Testing
- Bimagrumab
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD).
- Conditions
- Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Lambert-eaton Myasthenic Syndrome
- Trial name
- NCT07478172
- Testing
- Whole-body Electrical Muscle Stimulation Exercise
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Missouri-Columbia
Refractory Myositis
Treatment With TNF Blockade, Infliximab, in Patients With Myositis
This is a 4 month open trial with TNF-blockade using infliximab (an antibody that blocks TNF) in adult patients with chronic myositis (polymyositis, dermatomyositis, inclusion body myositis) who have persisting muscle weakness…
- Trial name
- NCT00443222
- Testing
- Infliximab
- Sponsor
- Karolinska Institutet
Dermatomyositis, Inclusion Body Myositis
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
Inflammatory myopathies are a group of muscle diseases characterized by muscle weakness, high levels of muscle enzymes in the blood, and inflammation of the tissue surrounding muscle fibers (endomysium).
- Conditions
- Dermatomyositis, Inclusion Body Myositis, Polymyositis
- Trial name
- NCT00001261
- Testing
- Gamma Globulin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Inclusion Body Myositis, Myotonic Dystrophy
The Risk of Falls Index for Patients With Neuromuscular Disorders
The combination of short quantitatively assessing muscular function and balance in combination with short clinical scores, can be a new valid approach to evaluate the patient risk of fall and help to create a quick checkup test…
- Conditions
- Inclusion Body Myositis, Myotonic Dystrophy, Facioscapulohumeral Muscular Dystrophies, Myasthenia Gravis
- Trial name
- NCT05890833
- Testing
- The risk of falls
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- LMU Klinikum
Sporadic Inclusion Body Myositis
Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis
The primary objective of the study is to evaluate the efficacy of REGN2477+REGN1033 in combination on total lean mass, as measured by Dual-energy X-ray absorptiometry (DXA) in patients with sporadic inclusion body myositis…
- Trial name
- NCT03710941
- Testing
- REGN2477+REGN1033
- Sponsor
- Regeneron Pharmaceuticals
Inclusion Body Myositis
A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM)
An open-label, ascending dose study for adult patients with Inclusion Body Myositis (IBM).
- Trial name
- NCT04659031
- Testing
- ABC008
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Abcuro, Inc.
Myositis, Inclusion Body
Alemtuzumab to Treat Sporadic Inclusion Body Myositis
This study will examine the safety and effectiveness of alemtuzumab (Campath® (Registered Trademark)) for improving muscle strength in patients with sporadic inclusion body myositis (s-IBM).
- Trial name
- NCT00079768
- Testing
- Alemtuzumab (Campath)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Inclusion Body Myositis
Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial
A multicenter, nonrandomized, open-label, uncontrolled clinical extension trial designed to compare the efficacy and safety of early versus delayed start of arimoclomol in the treatment of Inclusion Body Myositis (IBM)
- Trial name
- NCT04049097
- Testing
- Arimoclomol
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 121 people
- Sponsor
- ZevraDenmark